CTNNB1 and neoplasm: To explore the opportunity and potential benefit of targeted therapy for advanced and recurrent TBSCC, we sequenced the whole exomes of the tumor/normal tissues of the patient in our genetic test lab and identified several novel significantly mutated cancer genes that may be related to TBSCC including CTNNB1 and VEGFR-2 (Table 1).